Advertisement

Topics

Merck's sBLA for Keytruda to treat patients with advanced hepatocellular carcinoma gets US FDA priority review status

07:09 EDT 13 Jul 2018 | PharmaBiz

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License

Original Article: Merck's sBLA for Keytruda to treat patients with advanced hepatocellular carcinoma gets US FDA priority review status

NEXT ARTICLE

More From BioPortfolio on "Merck's sBLA for Keytruda to treat patients with advanced hepatocellular carcinoma gets US FDA priority review status"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...